✦ LIBER ✦

644 - Significantly improved survival with 'arimldex' (anastrozole (A)) compared with megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC): Updated results of two randomised trials

✍ Scribed by W. Jonat; A. Buzdar; A. Howell; A. Webster; K. Strutt

Book ID: 117664892
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 280 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85216-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

3. A randomized trial of the new specifi

3. A randomized trial of the new specific aromatase inhibitor ‘Arimidex’ (anastrozole) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (ABC)

✍ W. Jonat; A. Howell; C.P. Blomqvist; W. Eiermann; G. Winblad; C.J. Tyrrell; L. M 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 435 KB

Anastrozole versus megestrol acetate in

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma : Results of a survival update based on a combined analysis of data from two mature phase III trials

✍ Aman U. Buzdar; Walter Jonat; Anthony Howell; Stephen E. Jones; Carl P. Blomqvis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Medical University of BACKGROUND. This report presents the results of a survival update based on the combined data from two studies that compared the efficacy and tolerability of anastrozole (1 or 10 mg once daily), a selective, nonsteroidal aromatase inhibitor administered orally, and megestrol ace

Survival advantage of exemestane (EXE, A

Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

✍ E. Bajetta; L.Y. Dirix; L.E. Fein; S.E. Jones; J. Cervek; M. Kaufmann; C. Fowst; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 110 KB

Exemestane improves survival compared wi

Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: results of a double-blind randomised phase III trial

✍ M Kaufmann; E Bajetta; L.Y Dirix; L.E Fein; S.E Jones; J Cervek; C Fowst; A Poll 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 68 KB

PP-8-3 Double-blind trial in postmenopau

PP-8-3 Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA)

✍ I. Smith; P. Dombemowsky; G. Falkson; R. Leonard; L. Panasci; J. Bellmunt; W. Be 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 182 KB